PRA023 has tremendous possibilities for IBD and beyond

Our lead therapeutic candidate, PRA023, is a monoclonal antibody against cytokine TL1A, a target associated with both intestinal inflammation and fibrosis.

We’re now developing PRA023 for the treatment of Ulcerative Colitis, Crohn’s Disease, and Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), along with companion diagnostic products designed to help predict responses to identify the right patients for PRA023, with the goal of ensuring maximal response.  

Our biomarker-targeted therapeutic approach has the potential to advance a treatment paradigm similar to that pioneered in oncology, where the push for precision and increasingly targeted treatment has led to therapeutic decision-making based upon a patient’s biomarker profile—and transformed patient outcomes.

PRA023